<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37486567</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2509-8020</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>Journal of patient-reported outcomes</Title><ISOAbbreviation>J Patient Rep Outcomes</ISOAbbreviation></Journal><ArticleTitle>Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron.</ArticleTitle><Pagination><StartPage>77</StartPage><MedlinePgn>77</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">77</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s41687-023-00616-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Longitudinal estimates of long COVID burden during Omicron remain limited. This study characterized long-term impacts of COVID-19 and booster vaccination on symptoms, Health-Related Quality of Life (HRQoL), and Work Productivity Activity Impairment (WPAI).</AbstractText><AbstractText Label="METHODS">Outpatients with&#x2009;&#x2265;&#x2009;1 self-reported symptom and positive SARS-CoV-2 test at CVS Health United States test sites were recruited between 01/31 and 04/30/2022. Symptoms, EQ-5D and WPAI were collected via online surveys until 6&#xa0;months following infection. Both observed and model-based estimates were analyzed. Effect sizes based on Cohen's d quantified the magnitude of outcome changes over time, within and between vaccination groups. Mixed models for repeated measures were conducted for multivariable analyses, adjusting for covariates. Logistic regression assessed odds ratio (OR) of long COVID between vaccination groups.</AbstractText><AbstractText Label="RESULTS">At long COVID start (Week 4), 328 participants included 87 (27%) Boosted with BNT162b2, 86 (26%) with a BNT162b2 primary series (Primed), and 155 (47%) Unvaccinated. Mean age was 42.0&#xa0;years, 73.8% were female, 26.5% had&#x2009;&#x2265;&#x2009;1 comorbidity, 36.9% prior infection, and 39.6% reported&#x2009;&#x2265;&#x2009;3 symptoms (mean: 3.1 symptoms). At Month 6, among 260 participants, Boosted reported a mean of 1.1 symptoms versus 3.4 and 2.8 in Unvaccinated and Primed, respectively (p&#x2009;&lt;&#x2009;0.001). Boosted had reduced risks of&#x2009;&#x2265;&#x2009;3 symptoms versus Unvaccinated (observed: OR 0.22, 95% CI 0.10-0.47, p&#x2009;&lt;&#x2009;0.001; model-based: OR 0.36, 95% CI 0.15-0.87, p&#x2009;=&#x2009;0.019) and Primed (observed: OR 0.29, 95% CI 0.13-0.67, p&#x2009;=&#x2009;0.003; model-based: OR 0.59, 95% CI 0.21-1.65, p&#x2009;=&#x2009;0.459). Results were consistent using&#x2009;&#x2265;&#x2009;2 symptoms. Regarding HRQoL, among those with long COVID, Boosted had higher EQ-5D Utility Index (UI) than Unvaccinated (observed: 0.922 vs. 0.731, p&#x2009;=&#x2009;0.014; model-based: 0.910 vs. 0.758, p-value&#x2009;=&#x2009;0.038) and Primed (0.922 vs. 0.648, p&#x2009;=&#x2009;0.014; model-based: 0.910 vs. 0.708, p-value&#x2009;=&#x2009;0.008). Observed and model-based estimates for EQ-VAS and UI among Boosted were comparable with pre-COVID since Month 3. Subjects vaccinated generally reported better WPAI scores.</AbstractText><AbstractText Label="CONCLUSIONS">Long COVID negatively impacted HRQoL and WPAI. The BNT162b2 booster could have a beneficial effect in reducing the risk and burden of long COVID. Boosted participants reported fewer and less durable symptoms, which contributed to improve HRQoL and maintain WPAI levels. Limitations included self-reported data and small sample size for WPAI.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di Fusco</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0079-7331</Identifier><AffiliationInfo><Affiliation>Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USA. Manuela.difusco@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiaowu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>CVS Health, Woonsocket, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moran</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Groton, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coetzer</LastName><ForeName>Henriette</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CVS Health, Woonsocket, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamparo</LastName><ForeName>Joann M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Groton, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Mary B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Field Medical Outcomes and Analytics, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puzniak</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MDSCA Vaccines, Pfizer Inc, Collegeville, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabak</LastName><ForeName>Ying P</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>CVS Health, Woonsocket, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cappelleri</LastName><ForeName>Joseph C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Statistical Research and Data Science Center, Pfizer Inc, Groton, CT, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Patient Rep Outcomes</MedlineTA><NlmUniqueID>101722688</NlmUniqueID><ISSNLinking>2509-8020</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="N">BNT162 Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BNT162b2</Keyword><Keyword MajorTopicYN="N">Booster vaccine</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 symptoms</Keyword><Keyword MajorTopicYN="N">HRQoL</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">WPAI</Keyword></KeywordList><CoiStatement>MDF, MMM, JMZ, MBA, LP and JCC are employees of Pfizer and may hold stock or stock options of Pfizer. XS and HC are employees of CVS Health and may hold stock of CVS health. YPT was employee of CVS Health when current study was conducted.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>24</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>24</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37486567</ArticleId><ArticleId IdType="pmc">PMC10366033</ArticleId><ArticleId IdType="doi">10.1186/s41687-023-00616-5</ArticleId><ArticleId IdType="pii">10.1186/s41687-023-00616-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention. Long COVID or Post-COVID Conditions. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Accessed May 5, 2023.</Citation></Reference><Reference><Citation>Ledford H. How common is long COVID? Why studies give different answers. Nature. 2022;606(7916):852&#x2013;853. doi: 10.1038/d41586-022-01702-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-01702-2</ArticleId><ArticleId IdType="pubmed">35725828</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson M, Qasmieh S, Kulkarni S, Teasdale CA, Jones HE, McNairy M, Borrell LN, Nash D (2022) The epidemiology of long COVID in US adults two years after the start of the US SARS-CoV-2 pandemic. medRxiv</Citation></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, Rescigno M. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. 2022;328(7):676&#x2013;678. doi: 10.1001/jama.2022.11691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y (2022) Long COVID after breakthrough SARS-CoV-2 infection. Nat Med 28(7):1471&#x2013;1467</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, Peligro PJ, Casimiro M, Guerrero JJ, Gellaco MML. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine. 2022;53:101624. doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou GN, Baraff A, Fox A, Shahoumian T, Hickok A, O&#x2019;Hare AM, Bohnert AS, Boyko EJ, Maciejewski ML, Bowling CB. Rates and factors associated with documentation of diagnostic codes for long COVID in the national Veterans Affairs health care system. JAMA Netw Open. 2022;5(7):e2224359. doi: 10.1001/jamanetworkopen.2022.24359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.24359</ArticleId><ArticleId IdType="pmc">PMC9338411</ArticleId><ArticleId IdType="pubmed">35904783</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P (2022) Impact of COVID-19 vaccination on long COVID: a systematic review and meta-analysis. medRxiv. https://www.medrxiv.org/content/medrxiv/early/2022/06/22/2022.06.20.22276621.full.pdf.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Fusco M, Sun X, Moran MM, Coetzer H, Zamparo JM, Puzniak L, Alvarez MB, Tabak YP, Cappelleri JC (2022) Impact of COVID-19 and effects of BNT162b2 on patient-reported outcomes: quality of life, symptoms, and work productivity among US adult outpatients. J Patient Rep Outcomes 6:123</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9722994</ArticleId><ArticleId IdType="pubmed">36469198</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC/ATSDR Social Vulnerability Index. https://www.atsdr.cdc.gov/placeandhealth/svi/index.html Accessed 24 May 2021</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Updates&#x2014;Symptoms of COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. Accessed 5 May 2023.</Citation></Reference><Reference><Citation>Landry M, Bornstein S, Nagaraj N, Sardon Jr GA, Castel A, Vyas A, McDonnell K, Agneshwar M, Wilkinson A, Goldman L (2023) Postacute sequelae of SARS-CoV-2 in university setting. Emerg Infect Dis 29(3):519</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9973677</ArticleId><ArticleId IdType="pubmed">36703253</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, Safarpour A, Trujillo KL, Simonson MD, Green J, Quintana A, Druckman J, Baum MA. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open. 2022;5(10):e2238804. doi: 10.1001/jamanetworkopen.2022.38804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, Karamchandani U, Simms-Williams N, Cassambai S, Ardavani A. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. doi: 10.1016/j.eclinm.2022.101762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb M, Wang R, Yu H, Spatz ES, Montoy JC, Rodriguez R, Chang AM, Elmore JG, Hannikainen PA, Hill M (2023) Severe fatigue and persistent symptoms at three months following SARS-CoV-2 infections during the pre-delta, delta, and omicron time periods: a multicenter prospective cohort study. Clin Infect Dis 76(11):1930&#x2013;1941</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10249989</ArticleId><ArticleId IdType="pubmed">36705268</ArticleId></ArticleIdList></Reference><Reference><Citation>Spatz ES, Gottlieb M, Wisk LE, Anderson J, Chang AM, Gentile NL, Hill MJ, Huebinger RM, Idris AH, Kinsman J (2022) Three-month symptom profiles among symptomatic adults with positive and negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests: a prospective cohort study from the INSPIRE Group. Clin Infect Dis 75(9):1559&#x2013;1566</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11361781</ArticleId><ArticleId IdType="pubmed">36573005</ArticleId></ArticleIdList></Reference><Reference><Citation>EuroQol Research Foundation. (2019) EQ-5D-5L User Guide, Version 3.0. https://euroqol.org/publications/user-guides. Accessed 5 Aug 2021</Citation></Reference><Reference><Citation>Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, Oppe M, Boye KS, Chapman RH, Gong CL, Balch A, Busschbach JJV. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931&#x2013;941. doi: 10.1016/j.jval.2019.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2019.02.009</ArticleId><ArticleId IdType="pubmed">31426935</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353&#x2013;365. doi: 10.2165/00019053-199304050-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-199304050-00006</ArticleId><ArticleId IdType="pubmed">10146874</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly Associates (2002) WPAI Scoring. http://www.reillyassociates.net/WPAI_Scoring.html. Accessed 5 Aug 2021</Citation></Reference><Reference><Citation>Rosner B. Fundamentals of biostatistics. 8. Boston, MA: Cengage learning; 2015.</Citation></Reference><Reference><Citation>Freeman G, Halton JH. Note on an exact treatment of contingency, goodness of fit and other problems of significance. Biometrika. 1951;38(1/2):141&#x2013;149. doi: 10.2307/2332323.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2332323</ArticleId><ArticleId IdType="pubmed">14848119</ArticleId></ArticleIdList></Reference><Reference><Citation>Tukey J. Multiple comparisons. J Am Stat Assoc. 1953;48(263):624&#x2013;625.</Citation></Reference><Reference><Citation>Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. 2. Hoboken: Wiley; 2011.</Citation></Reference><Reference><Citation>Cohen J. Statistical power analysis for the behavioral sciences. 2. Hillsdale: Lawrence Erlbaum Assoc; 1988.</Citation></Reference><Reference><Citation>McLeod LD, Cappelleri JC, Hays RD (2016) Best (but oft-forgotten) practices: expressing and interpreting associations and effect sizes in clinical outcome assessments. Am J Clin Nutr 103(3):685&#x2013;93. Erratum: 2017; 105:241. 2016 10.3945/ajcn.115.120378. Erratum: 2017 10.3945/ajcn.116.148593</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4763495</ArticleId><ArticleId IdType="pubmed">26864358</ArticleId></ArticleIdList></Reference><Reference><Citation>STROBE Statement&#x2014;Checklist of items that should be included in reports of cohort studies. https://www.strobe-statement.org/download/strobe-checklist-cohort-studies-pdf. Accessed 5 Aug 2022</Citation><ArticleIdList><ArticleId IdType="pubmed">18522360</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren O, Stehlik P, Clark J. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. 2023;2:e000385. doi: 10.1136/bmjmed-2022-000385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000385</ArticleId><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamm TA, Partheym&#xfc;ller J, Mosor E, Ritschl V, Kritzinger S, Alunno A, Eberl J-M. Determinants of COVID-19 vaccine fatigue. Nat Med. 2023;29(5):1164&#x2013;1171. doi: 10.1038/s41591-023-02282-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02282-y</ArticleId><ArticleId IdType="pmc">PMC10202806</ArticleId><ArticleId IdType="pubmed">36973410</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers RW (1983) Cognitive and psychological processes in fear appeals and attitude change: a revised theory of protection motivation. Social psychophysiology: a sourcebook. Guilford Press, New York, pp 153&#x2013;176</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>